MOTS-c: A Peptide Encoded by the Mitochondria

Mitochondria carry their own small genome, a remnant of the bacteria they descend from. For most of the history of cell biology that genome was understood to encode components of the respiratory chain and little else. MOTS-c complicated that picture.

Where it comes from

MOTS-c — mitochondrial open reading frame of the twelve S rRNA type-c — is a sixteen-amino-acid peptide encoded within the mitochondrial 12S ribosomal RNA gene. It was described by Lee and colleagues in Cell Metabolism in 2015 [1]. The finding of interest was not simply that the peptide existed, but that it appeared to act outside the mitochondrion, on the cell around it and on distant tissue.

That places it in a small category sometimes described as mitochondrial-derived peptides: molecules that suggest the mitochondrial genome participates in signalling rather than only in energy production.

The mechanism described

The 2015 work reported that MOTS-c acts principally on skeletal muscle, interfering with the folate cycle and the purine synthesis pathway that depends on it. The consequence of that interference is accumulation of an intermediate that activates AMPK — the enzyme cells use to sense low energy and switch toward generating it rather than storing it.

AMPK is a well-characterised metabolic switch, which is why this route attracted attention: it connects a mitochondrial peptide to a pathway already understood in detail.

What was actually observed

In the reported experiments, MOTS-c administration in mice prevented insulin resistance associated both with age and with a high-fat diet, and reduced diet-induced obesity. Subsequent work has examined circulating MOTS-c levels in relation to metabolic state and exercise.

The essential qualifier: this is animal and cell work. Human clinical trials of the kind that exist for tesamorelin or semaglutide have not been conducted for MOTS-c, and no regulator has reviewed it.

Reading the evidence honestly

• The mechanism is described in cell and rodent models, not demonstrated in humans.
• Observational findings about circulating levels show association, not cause.
• There is no approved indication and no regulatory review of safety.
• Compared with GLP-1-class compounds that have been through phase 2 or phase 3 trials, the evidence base here is early.

Handling

Supplied lyophilized and reconstituted with bacteriostatic water. As a short peptide it is straightforward to dissolve; the usual rules apply — bring the vial to room temperature before opening, swirl rather than shake, refrigerate once in solution.

Supplied for laboratory and research use only. Given how early this literature is, treat confident claims about MOTS-c — including elsewhere on the internet — with suspicion.

1. 1.Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443–454.